Cannabis News
Authoritative coverage of the global cannabis industry — regulation, investment, markets and policy, reported for the people who run it.
Cannabis News · page 71
- Adult-Use
Cannabis Business Licenses Decline in 2024 Amid Regulatory Restructuring and Market Tightening
The number of active US cannabis business licenses – including those in regulated medical and recreational markets – continued to decline through the third quarter of 2024 as reductions in established markets outpaced growth in emerging ones.
- Uncategorized
DEA Accused of ‘Stacking the Deck’ Against Rescheduling in Hearing Selection
US cannabis rescheduling has come under yet more controversy this week as the US Drug Enforcement Administration (DEA) has been accused of stacking participants with opponents of cannabis reform.
- Markets & Stocks
Celadon Hit by Cash Crunch Amid Funding Delays, Danish Companies Spike on Medical Cannabis Expansion, & Tilray Launches German Grown Products
Celadon Pharmaceuticals [stock_market_widget type=”chart” template=”line” assets=”CEL.L” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] UK-based medical cannabis producer Celadon Pharmaceuticals has seen its stock tank by 40% this week as its funding crisis hits a critical juncture.
- Uncategorized
Canada’s Cannabis Industry Braces for Nationwide Postal Strike
Canadian cannabis operators are preparing their businesses for a nationwide postal strike on Friday, which involves 55,000 postal workers.
- Uncategorized
Note Draws Speculation DEA May Expand Participant List for Cannabis Rescheduling Hearings Next Year
Ahead of the delayed and highly anticipated cannabis rescheduling hearings, now set to take place in early 2025, the US Drug Enforcement Administration (DEA) has suggested it could add more participants.
- Uncategorized
Deutschlands Importe von medizinischem Cannabis wachsen im 3. Quartal um 70%, da der Markt weiter explodiert
Das deutsche Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) hat die Importzahlen für medizinisches Cannabis für das dritte Quartal veröffentlicht, die zeigen, dass der Markt für medizinisches Cannabis in Deutschland weiterhin schnell wächst.
- Medical
Germany’s Medical Cannabis Imports Grow 70% in Q3 as Market Explosion Continues
Germany’s Federal Institute for Drugs and Medical Devices (BfArM) has published the medical cannabis import figures for Q3, showing that the country’s medical cannabis market is still growing rapidly.
- Uncategorized
USDA Delays Enforcement of DEA Lab Testing Rule for Hemp Growers Until 2025
The US Department of Agriculture (USDA) has announced a third consecutive delay in enforcing a rule requiring hemp growers to test their crops exclusively at laboratories registered with the Drug Enforcement Administration (DEA).
- Uncategorized
Deutschlands wahlentscheidende Partei will Cannabis-Reformen vor den Wahlen rückgängig machen
Auch wenn in der Debatte am Freitag kaum Gemeinsamkeiten gefunden wurden, unterstrich die abgedroschene Rhetorik beider Seiten, dass die Umsetzung des CanG in Deutschland nach wie vor ein kontroverses und spaltendes Thema ist.
- Policy & Regulation
Germany’s Poll-Leading Party Eyes Rollback of Cannabis Reforms as Elections Loom
While little common ground was found during Friday’s debate, the well-trodden rhetoric from each side emphasised that the implementation of CanG remains a controversial and divisive issue in Germany.
- Uncategorized
Cannabis Rescheduling: Stakeholders Balance Support with Caution Ahead of DEA Hearing
The next step in the yearslong cannabis rescheduling process could be a brief hearing where an administrative law judge informs witnesses why they aren’t qualified to participate, observers told MJBizDaily.
- Uncategorized
What do Trump’s Cabinet Picks Mean for Cannabis Reform?
As the furor surrounding the US presidential election subsides, the president elect’s preliminary picks for his cabinet have given the cannabis industry a glimpse into what it can expect for reform in the US over the next four years.
